Recently disclosed in Nature , Janssen’s JNJ-1802 is the first dengue virus NS3-NS4B protein-protein interaction inhibitor to enter the clinic. The molecule is derived from a related chemical series to JNJ-A07 , which was also disclosed in Nature in 2021 and highlighted as a Molecule of [...]
8 minute read
Apr. 29, 2023
The First Dengue NS3-NS4B Inhibitor to Enter the Clinic
JNJ-1802
oral first-in-class DENV (NS3-NS4B) inhibitor Ph. I for dengue from a DENV-2 phenotypic antiviral screen Nature, March 15, 2023 Janssen, BE + FR
Loading...
